News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer
Evandro de Azambuja/LinkedIn
Sep 8, 2025, 11:43

Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer

Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared a post on LinkedIn:

“Our group just reflected on this important issue on managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: An Emerging Challenge.”

Title: Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge

 Authors: R. Gerosa, G. Gentile, L. Arecco, C. Dauccia, S. Nannini, S. Lobo-Martins, E. Agostinetto, M. Lambertini, A. Santoro, P. Aftimos, M. Piccart-Gebhart, E. de Azambuja

Read the Full Article.

Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer

More from Evandro de Azambuja on OncoDaily.

A. Santoro C. Dauccia cancer E. Agostinetto E. de Azambuja Evandro de Azambuja G. Gentile L. Arecco M. Lambertini M. Piccart-Gebhart OncoDaily Oncology P. Aftimos R. Gerosa S. Lobo-Martins S. Nannini
Special Coverage
Insight
Sep 8, 2025, 11:43
Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer
Science
Sep 8, 2025, 11:35
David Planchard Presents Planned OS Results from FLAURA2 Phase III at WCLC25
Voices
Sep 8, 2025, 11:33
Sewanti Limaye: Honored to Co-Chair EGFR+ Session at WCLC 2025
Positive
Sep 8, 2025, 11:29
Celebrating Excellence at Cancer Institute NSW: September Staff Awards
Voices
Sep 8, 2025, 11:28
Douglas Flora: Minimal Residual Disease Beyond the Smoke - How We're Using Science to Find What's Left Behind 
Voices
Sep 8, 2025, 11:21
Rami Manochakian Shares MARIPOSA Study Results Presented at WCLC25
Voices
Sep 8, 2025, 11:19
Sendurai Mani: Farewell to Dr. David Baltimore, a Pioneer and Inspiration
Voices
Sep 8, 2025, 11:11
Ilana Schlam: Free NEJM CME Course on Advanced ER+/HER2− Breast Cancer Treatments
Insight
Sep 8, 2025, 11:00
Gevorg Tamamyan: A Story Everyone Must Read
Insight
Sep 8, 2025, 10:52
WCLC25: Insights and Highlights from Dr. Stephen Liu
Voices
Sep 8, 2025, 09:53
David Planchard Highlights FLAURA2 OS Benefit Discussion at WCLC 2025
Science
Sep 8, 2025, 09:46
Amol Akhade: WCLC25 Highlight - HARMONi-A Trial in EGFR-mutant NSCLC